TCT 2021 | Long-term outcomes of VRD, auto-HCT with Mel200 conditioning & lenalidomide maintenance in MM
Mahmoud Gaballa
• 5 Feb 2021
Mahmoud Gaballa, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a retrospective analysis evaluating long-term outcomes of patients with multiple myeloma treated with VRD induction (bortezomib, lenalidomide, and dexamethasone), followed by autologous hematopoietic stem cell transplantation (auto-HCT) with melphalan 200mg/m2 (Mel200) conditioning and lenalidomide maintenance. This regimen is found to be associated with very good outcomes in patients with multiple myeloma, especially those with standard-risk cytogenetics and complete response as their best final response. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
